Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2006-04-04
2006-04-04
Parkin, Jeffrey S. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S208100
Reexamination Certificate
active
07022324
ABSTRACT:
This invention provides an isolated nucleic acid which comprises a nucleotide segment having a sequence encoding a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention also provides a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention further provides methods of treating HIV-1 infection.
REFERENCES:
patent: 5474914 (1995-12-01), Spaete
patent: 5886163 (1999-03-01), Hasel et al.
patent: 5935579 (1999-08-01), Habeshaw et al.
patent: 6171596 (2001-01-01), Earl et al.
Burton, D.R. et al. (1994) Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266: 1024-1027.
Labranche, C.C. et al. (1994) Biological, molecular, and structural analysis of a cytopathic variant from a molecularly cloned simian immunodeficiency virus. J. Virol. 68(9): 5509-5522.
Labranche, C.C. et al. (1994) Biological, molecular, and structural analysis of a cytopathic variant from a molecularly cloned simian immunodeficiency virus. J. Virol. 68(11): 7665-7667.
Trkola, A. et al. (1996) Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70(2): 1100-1108.
Binley, J., et al., (2000) “A Recombinant Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Complex Stabilized By An Intermolecular Disulfide Bond Between The GP 120 and GP 41 Subunits Is An Antigenic Mimic Of The Trimeric Viron-Associated Structure”, Journal of Virology, vol. 74, No. 2, 627-643 (Exhibit B).
Farzan, M., et al. (1998) “Stabilization Of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trimers By Disulfide Bonds Introduced Into The GP 41 Glycoprotein Ectodomain”, Journal of Virology, vol. 72, No. 9, 7620-7625 (Exhibit C).
Farzan, M., et al., 1998, “Stabilization of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trimers by Disulfide Bonds Introduced into the gp41 Glycoprotein Ectodomain”, J. Virol. 72(9):7620-7625.
Haynes, B.F., et al., 1996, “Update on the issues of HIV Vaccine Development”, Ann. Med. 28:39-41.
Burton, D. R., and J. P. Moore, 1998, “Why do we not have an HIV vaccine and how can we make one?”, Nature Med. Vaccine Suppl. 4(5):495-498.
Letvin, N. L., 1998, “Progress in the Development of an HIV-1 Vaccine”, Science 280:1875-1880.
Binley, J. M., et al., 2000, “A Recombinant Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Complex Stabilized by an Intermolecular Disulfide Bond between the gp120 adn gp41 Subunits Is an Antigenic Mimic of the Trimeric Virion-Associated Structure”, J. Virol. 74(2):627-643.
Cao, J., et al., 1993, “Effects of Amino Acid Changes in the Extracellular Domain of the Human Immunodeficiency Virus Type 1 gp41 Envelope Glycoprotein”, J. Virol. 67(5):2747-2755.
Maerz, A. L., et al., 2001, “Functional Analysis of the Disulfide-Bonded Loop/Chain Reversal Region of Human Immunodeficiency Virus Type 1 gp41 Reveals a Critical Role in gp120-gp41 Association”, J. Virol. 75(14):6635-6644.
Atwell, S. et al. (1997) Stable Heterodimers form Remodelling the Domain Interface of a Homodimer using a Phage Display Library, J. Mol. Biol. 270: 26-35.
Barouch, D.H. and N.L. Letvin (2000) DNA Vaccination for HIV-1 and SIV, Intervirol, 4: 282-287.
Barouch, D.H. et al. (2002) Eventual AIDS Vaccine Failure in a Rhesus Monkey by Viral Escape from Cytotoxic T Lymphocytes, Nature 415: 335-339.
Burton, D.R. and J.P. Moore (1998) Why do we Not Have an HIV Vaccine and how Can we Make One? Nature Med, Vaccine Suppl. 4(5): 495-498.
Cao, J. et al. (1997) Replication and Neutralization of Human Imunodeficiency Virus Type 1 Lacking the V1 and V2 Variable Loops of the gp120 Envelope Glycoprotein. J. Virol. 71: 9808-9812.
Edinger, A.L. et al. (1999) Functional Dissection of CCR5 Coreceptor Function through the Use of CD4-Independent Simian Immunodeficiency Virus Strains, J. Virol. 73: 4062-4073.
Fouts, T.R. et al. (1998) Interactions of Polyclonal and Monoclonal Anti-Glycoprotein 120 Antibodies and Oligomeric Glycoprotein 120-Glycoprotein 41 Complexes of a Primary HIV Type 1 Isolate: Relationship to Neutralization, AIDS Res. Human Retrovir. 14: 591-597.
Fouts, T.R. et al. (1997) Neutralization of the Human Immunodeficiency Virus Type 1 Primary Isolate JR-FL by Human Monoclonal Antibodies Correlates with Antibody Binding to the Oligomeric Form of the Envelope glycoprotein Complex, J. Virol. 71: 2779-2785.
Gallaher, W.R. et al. (1995) A General Model for the Surface Glycoproteins of HIV and Other Retroviruses, AIDS Res. Human Retrovir. 11: 191-202.
Helseth, E. et al. (1991) Human Immunodeficiency Virus Type 1 gp120 envelope Glycoprotein Regions Important for Association with the gp41 Transmembrane Glycoprotein, J. Virol. 65(4): 2119-2123.
Haynes, B.F. (1996) HIV Vaccines: Where are we and Where are we Going? Lancet 348: 933-937.
Johnston, M.I. and J. Flores (2001) Progress in HIV Vaccine Development, Curr. Opin. Pharmacol. 1(5): 504-510.
Joy, A.K. et al. (1999) Can HIV Infection be Prevented with a Vaccine? Drugs R&D 6: 431-440.
Maerz, A.L. et al. (2001) Functional Analysis of the Disulfide-Bonded Loop/Chain Reversal Region of Human Immunodeficiency Virus Type 1 gp41 reveals a Critical Role in gp120-gp41 Association, J. Virol. 75(14): 6635-6644.
McInermey, T.L. et al. (1998) Mutation-Directed Chemical Cross-Linking of Human Immunodeficiency Virus Type 1 gp41 Oligomers, J. Virol. 72: 1523-1533.
Mitchell, W.M. et al. (1998) Inactivation of a Common Epitope Responsible for the Induction of Antibody-Dependent Enhancement of HIV, AIDS 12: 147-156.
Moore, J.P. et al. (1994a) Probing the Structure of the Human Immunodeficiency Virus Surface Glycoprotein gp120 with a Panel of Monoclonal Antibodies, J. Virol. 68: 469-484.
Moore, J.P. et al. (1994b) Immunological Evidence for Interactions between the First, Second, and Fifth Conserved Domains to the gp120 Surface Glycoprotein of Human Immunodeficiency Virus Type 1, J. Virol. 68(11): 6836-6847.
Murphy, F.A. (1996) “Virus Taxonomy,” in Fields Virology, Third Edition, Fields, B.N., et al. eds., Lippincott-Raven Publisher, Philadelphia, pp. 40 and 41.
Parren, P.W. et al. (1997) HIV-1 Antibody—Debris or Virion? Nat. Med. 3: 366-367.
Parren, P.W. et al. (1998) Neutralization of Human Immunodeficiency Virus Type 1 by Antibody to gp120 is Determined Primarily by Occupancy of Sites on the Virion Irrespective of Epitope Specificity, J. Virol. 72: 3512-3519.
Reitter, J.N. et al. (1998) A Role for Carbohydrates in Immune Evasion in AIDS, Nat. Med. 4: 679-684.
Schulz, T.F. et al. (1992) Conserved Structural Features in the Interaction between Retroviral Surface and Transmembrane Glycoproteins? AIDS Res. Hum. Retrovirus 8(9): 1571-1580; and.
Starnatatos, L. et al. (1994) Differential Regulation of Cellular Tropism and Sensitivity to Soluble CD4 Neutralization by the Envelope gp120 of Human Immunodeficiency Virus Type I, J. Virol. 68: 4973-4979.
Binley James M.
Maddon Paul J.
Moore John P.
Olson William C.
Schuelke Norbert
Cooper & Dunham LLP
Parkin Jeffrey S.
Progenics Pharmaceuticals Inc.
White John P.
LandOfFree
Stabilized viral envelope proteins and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stabilized viral envelope proteins and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stabilized viral envelope proteins and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3584205